טוען...
Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
BACKGROUND: Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP). METHODS AND RESULTS: Retrospective cohort study of patients taking QDay lisinopril and losartan who experienced a dose-doubling (index date)....
שמור ב:
| הוצא לאור ב: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7714357/ https://ncbi.nlm.nih.gov/pubmed/33270787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0243371 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|